SCHEMBL10274463

SCHEMBL10274463

CCc1ccc2c(c1)OC(C)O2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
TRPA1 O75762 1/20 0.39
CYP1A2 P05177 2/20 0.38
PARP1 P09874 1/20 0.38
CYP2A6 P11509 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.34
ATM Q13315 1/20 0.34
LMNA P02545 2/20 0.33
MAPT P10636 2/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
HCRTR2 O43614 1/20 0.32
TP53 P04637 1/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10274494 0.84 CNR1 (0.41) PTGS2LMNAALDH1A1TAAR1
SCHEMBL12672866 0.82 PARP1 (0.44) PTGS1PTGS2TRPA1CYP1A2PARP1
SCHEMBL9145627 0.79 PTGS2 (0.46) PTGS2MAPTALDH1A1BRD4
SCHEMBL12463955 0.79 PTGS1 (0.41) PTGS1PTGS2TRPA1CYP1A2PARP1
SCHEMBL11854767 0.79 CYP1A2 (0.36) PTGS1PTGS2CYP1A2PARP1MAPT
SCHEMBL28732003 0.77 CYP3A4 (0.54) PTGS1CYP1A2PARP1LMNAMAPT
SCHEMBL17071893 0.76 PARP1 (0.40) PTGS1PTGS2CYP1A2PARP1LMNA
SCHEMBL31545111 0.76 TAAR1 (0.58) TAAR1
SCHEMBL30609582 0.76 SIGMAR1 (0.39) PTGS2LMNAALDH1A1MAPK1MEN1
SCHEMBL22795922 0.74 PARP1 (0.39) PTGS1PTGS2TRPA1PARP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10308595-B2 Albicidin derivatives, their use and synthesis Technische Universität Berlin (DE) 2019-06-04 US disclosed
US-20120028920-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. 2012-02-02 US disclosed
EP-2287161-A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders Otsuka Pharmaceutical Co., Limited (JP) 2011-02-23 EP disclosed
EP-2287162-A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders Otsuka Pharmaceutical Co., Ltd. (JP) 2011-02-23 EP disclosed
EP-2284169-A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders Otsuka Pharmaceutical Co., Limited (JP) 2011-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10308595-B2 Albicidin derivatives, their use and synthesis MB, ALB, BCAT2 PTGS1 2516/4885PTGS2 3138/4885TRPA1 4539/4885
US-20120028920-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS GRIN2C, GRIN2B, PMP22 PTGS1 1551/4885PTGS2 2218/4885TRPA1 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.